Glenmark manufactures and markets generic formulation products and other pharmaceutical ingredients.

What section would you like to update?
  • Company Logo
  • Company Name & URL
  • Company Description
  • Founded Date
  • Company Status
  • HQ Address
  • Social Links
  • CEO Name & Picture
  • Competitor Set
  • Funding Events
  • Acquisition Events

If you'd like to make any changes to this portfolio we'd be happy to help. Please send info/sources to support@owler.com.


We'll be back up as soon as possible.

Visit owler.uservoice.com for FAQs

Glenmark Revenue, Funding, Number of Employees, Competitors and Acquisitions

GLENMARK CEO

Glenn Saldanha

CEO

Glenn Saldanha

Approval Rating: 82/100

WEIGH-IN

How would you rate Glenn Saldanha as a CEO?

negative
You
neutral
You
positive
You

Founded:

1977

Headquarters:

MumbaiMaharashtra

Status:

PublicBombay Stock Exchange532296

Industry Sector:

Pharmaceuticals

Completeness:

100%

KEY STATS

Revenue

- -

What is Glenmark's revenue?

<1M

Employees

- -

How many people work at Glenmark?

Followers on Owler

- -

FOLLOW
UNFOLLOW

TOP COMPETITORS

Add a new competitor:

Thanks for your contribution!

Recalculating The Competitive Graph now...

ADD

Glenmark was founded in 1977 and its headquarters is located in Mumbai, Maharashtra, IN. Glenmark has $824.9M in revenue and 7000 employees. Glenmark's top competitors are Dr.Reddy's, Sun Pharma and Zydus.

Glenmark Competitive Set

COMPANYLEADERSHIPCEO SCORE

EMPLOYEES
(ESTIMATED IF PRIVATE)

TOTAL FUNDING

REVENUE
(ESTIMATED IF PRIVATE)

LIKELY OUTCOME
GlenmarkGlenmark ceo

Glenn Saldanha

CEO

82/100
1Dr.Reddy's ceoDr.Reddy's

G V Prasad

CEO

76/10022,671
$2.2B
2Sun Pharma ceoSun Pharma

Dilip S. Shanghvi

Managing Director

72/10030,000
$4.4B
3Zydus ceoZydus

Pankaj R. Patel

Managing Director

76/10012,227
$54.7B
4Aurobindo Pharma ceoAurobindo Pharma

Govindarajan Narayanan

Managing Director

74/10013,288
$1.6B
5Jubilant Life Sciences ceoJubilant Life Sciences

Hari S. Bhartia

Managing Director

69/1002,389
$925.4M
6Cadila Pharmaceuticals ceoCadila Pharmaceuticals

Dr. Rajiv I. Modi

Managing Director

50/100
$100M
7Reliance Life Sciences ceoReliance Life Sciences

K.V. Subramaniam

President & CEO

84/100
$10M
8Serum Institute of India ceoSerum Institute of India

Adar C. Poonawalla

CEO

56/100200

Glenmark Revenue History

company revenue img

Coming soon with Owler Pro!

If you'd like to learn more, please contact us at support@owler.com

$

Community Estimate

UPDATE THIS

Glenmark Employee History

company revenue img

Coming soon with Owler Pro!

If you'd like to learn more, please contact us at support@owler.com

Community Estimate

UPDATE THIS

Glenmark Leadership

NAMETITLESOCIAL MEDIA
Glenn Saldanha
Glenn Saldanha

CEO

CEO

Glenmark News

Glenmark: Glenmark to commercialize six SCD eye products in the North AmericaSouth Korea's Sam Chun Dang (SCD) Pharm has signed a 600 million won ($558,000) deal to license out...The Pharma Letter
Glenmark: Glenmark ties up with S. Korea's SCD for ophthalmic products Glenmark Pharmaceuticals has entered into an exclusive agreement with South Korea's Sam Chun Dang Pharm Co Ltd (SCD) to develop, manufacture and market a portfolio of ophthalmic products in the USThe Hindu Business Line
Glenmark: BRIEF-Glenmark Pharma Enters Exclusive Collaboration Agreement with SCD Pharmaceuticals* GLENMARK PHARMACEUTICALS - ‍ENTERED INTO EXCLUSIVE DEAL WITH SAM CHUN DANG PHARMReuters
Glenmark: Glenmark Pharmaceuticals Presents New Data on GBR 830 at the 2018 American Academy of Dermatology Annual MeetingGlenmark Pharmaceuticals Presents New Data on GBR 830 at the 2018 American Academy of Dermatology Annual Meeting...Equity Bulls
Glenmark: Q3: Operating performance was below parGlenmark's Q3FY18 operating performance was lower than our estimates. Net revenues at `22 bn were down 13% y-o-y, 0.8% lower than our expectations.The Financial Express
Press Release: Glenmark : Melasma (Chlosma) Professional Survey about Therapeutics and Pipeline Review H2 2018PUNE, MAHARASHTRA, INDIA, February 12, 2018 /EINPresswire.com/ -- WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report "Melasma (Chlosma) Global Clinical Trials Review, H2, 2018"...EIN Presswire
Glenmark: Despite poor Q3, HDFC Securities maintains BUY rating for Glenmark; here's whyHDFC Securities in a note has maintained a Target Price of Rs 780 on Glenmark and maintained a why. This is what they had to say:Glenmark's Q3 (FY 2017-18) performance was sub-par, as pricing pressure in the US business, higher R&D and forex losses weighed on profits.While Year on Year comparisons are not apt on account of the exclusive launch of gZetia in 3QFY17, the top-line declined by 2% quarter on quarter to Rs 21.7 billion (in-line with estimates).EBITDA margin disappointed at 13.4% (vs expectation of 18%), down 260 basis point (2.6%) quarter on quarter.Gross margins declined by 220 basis points quarter on quarter on the back of an inferior business mix, and R&D costs remained elevated (12.9% of sales vs 12% QoQ).Profit after Tax was Rs 935 million, dragged down by 54% quarter on quarter by forex losses of Rs 480 million (vs gain in 2QFY18).The management believes that 3QFY18 is the bottom for revenues and margins and HDFC Securities say they are inclined to agree.However, the steep US erosion guidance of 13% going forward will only be offset with lucrative launches.We continue to believe that Glenmark's push towards innovation and specialty is strategically sound. However, the capital allocation is weighing heavily on the business at present, especially at a time when launch momentum in the US is sluggish.The lingering debt and deteriorating margin profile lead us to cut our earnings estimates by 22%/14% for FY19/20E and earnings multiple from 18x to 16x. Foresee 6%/14% revenue/earnings CAGR over FY17-20E.Maintain BUY with a revised Target Price of Rs 780 (16x Dec-19E and Rs 135/sh for pipeline).Highlights of the quarterUS business: There was a wide miss on management guidance of US$ 125 million in 3QFY18, with sales of US$ 113 million.Glenmark has also guided for 13% base business erosion upto FY20E, much higher than peer commentary.Generic competition in mupirocin is anticipated in the coming six months. Considering these factors, we have cut our US revenue estimates. Foresee 6% Compound Annual Growth Rate in the base business (ex-Zetia) over FY17 - 20E.Other highlights:(1) 8% of sales is being spent just on specialty and innovation R&D(2) Expect gEpiduo to be an early FY19E launch(3) GSP 301 filing in next 2-3 months(4) Provided comprehensive response to the USFDA on Baddi 483, awaiting response5) See domestic business growth at 15%+ for the coming years(6) Cost optimisation measures will yet to play out, the benefit will be seen over the next couple of years(7) DTA adjustment one-off was Rs 52 million. Near-term outlook: Management has guided for a margin recovery in 4QFY18. Execution remains to be seen.Samachar
Glenmark: Pharma weekly wrap: Lupin, Glenmark post nos; Singh brothers resign from Fortis boardThe highlights of the week include resignation Malvinder and Shivinder Singh promoters of Fortis from the Board and Q3 results of some major pharmaceutical companies.moneycontrol
Glenmark: GLENMARK PHARMA SHARES DIVE NEARLY 10% AFTER Q3 EARNINGSNew Delhi: Shares of Glenmark Pharmaceuticals today slumped nearly 10 per cent a day after the company reported a 78 per cent fall in net profit for the quarter ended December.btvi
Glenmark: Glenmark Pharma tanks 9% after disappointing Q3 earnings, US pricing pressure to continueWhile addressing conference call, Glenn Saldanha, Chairman and MD said the US business continued to be very challenging and that pricing pressure would remain challenging for 5 quarters.Moneycontrol

SEE MORE

SEE LESS

Glenmark Website History

Screengrabs of how the Glenmark site has evloved. (Click to expand)

Glenmark website history

Sep 2017

Glenmark website history

Sep 2017

Glenmark website history

May 2017

Glenmark website history

Jan 2017

Glenmark website history

Oct 2016

Glenmark website history

Jul 2016

Glenmark website history

Apr 2016

Glenmark website history

Jan 2016

Glenmark website history

Oct 2015

Glenmark website history

Jul 2015

Glenmark website history

Apr 2015

Glenmark website history

Nov 2014

Glenmark website history

Aug 2014

Glenmark website history

May 2014

Owler has collected 14 screenshots of Glenmark's website since May 2014. The latest Glenmark website design screenshot was captured in Sep 2017.

Glenmark Headquarters

undefined company logo

Glenmark House, B D S Marg, Chakala, Off Western Express Highway Andheri (E)

Mumbai, Maharashtra 400099

91-22-4018-9999

Driving Directions

google map

Glenmark Summary Information

Glenmark manufactures and markets generic formulation products and other pharmaceutical ingredients. Glenmark was founded in 1977. Glenmark's headquarters is located in Mumbai, Maharashtra, IN 400099. Glenmark's CEO, Glenn Saldanha, currently has an approval rating of 82%. 57% of Owler community believes the stock will go Up. Glenmark has 7000 employees and reported 824.9M in revenue [trailing four quarters].

Glenmark's CEO, Glenn Saldanha, currently has an approval rating of 82%. Glenmark's primary competitors are  Dr.Reddy's Sun Pharma Zydus.

Visit the Glenmark website to learn more.